Healthcare Industry News: Ophthalmic Imaging Systems
News Release - August 19, 2015
Clarity Medical Systems Adds Key Members to Executive Leadership
New Hires Contribute to Infrastructure Needs to Meet Company’s ExpansionPLEASANTON, Calif.--(Healthcare Sales & Marketing Network)--Clarity Medical Systems, Inc. announced today the hiring of several new key members of its Executive Leadership Team. These executives will initially focus on the commercial introduction of Clarity’s upcoming product, HOLOS IntraOP™, a continuous real-time intraoperative aberrometer for refractive cataract surgery. Clarity is a leader in the development, manufacturing, and marketing of integrated optical systems and services that enhance the clinician’s ability to diagnose manage and treat eye disorders.
“Clarity has assembled an experienced, high-powered leadership team with deep medical device skill sets. These recent hires are particularly suited to help us meet our 2015 HOLOS product launch objectives. Additionally, they will be key resources for our on-going and future product innovation efforts as we continue to expand Clarity’s ophthalmic platform,” said President and CEO Mark Mellin.
John P. Farugia has been hired as Vice President & Chief Marketing Officer. Farugia brings a wealth of experience in sales and marketing of medical devices having most recently served as Senior Director, Global Marketing with Vidacare Corporation, a vascular access medical device company, which was sold to Teleflex Incorporated. Prior to Vidacare, Farugia served a long tenure with Kinetic Concepts Inc., and was instrumental in the company’s expansion into several key international markets, including Brazil and Japan, as well as managing new product launches both domestically and internationally.
Eric Steuben is the new Vice President of Operations and RA/QA and is responsible for manufacturing, regulatory affairs, quality assurance, supply chain, logistics and technical services. Steuben joins Clarity after previously working for Asante Solutions, Inc. a manufacturer of insulin pumps, where he led the commercialization and scale up of manufacturing including transfer to offshore facilities. Prior to that, he led manufacturing, engineering and operations’ teams at Align Technology and Microdental Laboratories.
Michael M. Manteiga joins Clarity as Vice President of Sales. He previously served as the Vice President of Sales for Optos, Inc., a manufacturer of ultra-widefield retinal imaging devices. Prior to Optos, Manteiga held sales and management roles for United States Surgical and Baxter Health Care in their surgical divisions.
Wenkang Qi, PhD, joins Clarity as Vice President of Research & Development and Chief Technology Officer after serving as Vice President of Asante Solutions, Inc., where he led research and development of the company’s insulin pump technology. Prior to Assante, Qi held leadership roles in the R & D department of Vasa Nova as well as engineering roles at GE Medical Systems and ZONARE.
About Clarity Medical Systems, Inc.
Clarity Medical Systems, Inc., develops, manufactures and markets advanced newborn and pediatric Ophthalmic Imaging Systems, guidance and informatics tools that enhance the clinician’s ability to diagnose, manage, and treat eye disorders. Clarity’s HOLOS IntraOp™, is a continuous real-time intraoperative aberrometer for refractive cataract surgery. HOLOS IntraOp is designed to provide high-accuracy, real-time, intraoperative refractive guidance and data throughout all phases of surgery to assist physicians in better achievement of their patients’ refractive goals.
The company’s RetCam™ product line is helping to improve the quality of eye healthcare in the pediatric populations worldwide and is sold to leading Neonatal Intensive Care Units on a global basis. To date, over 1,800 RetCam™ systems have been installed and the eyes of more than one million children have been imaged in over 85 countries.
Source: Clarity Medical Systems
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
